Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

34 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Hypereosinophilia and Hypereosinophilic Syndromes: First Findings From a Nationwide Multicenter Cohort.
Lefèvre G, Bleuse S, Puyade M, Moulis G, Néel A, Abisror N, Baudet A, Bonnotte B, Dion J, Dossier A, Grall M, Lifermann F, Limal N, Lioger B, Machelart I, Mohr C, Outh R, Queyrel-Moranne V, Slama B, Tréfond L, Abou Chahla W, Ackerman F, Belfeki N, Berezne A, Blade JS, Bouderbala MA, Chebrek S, Cottin V, De Almeida S, De Masson A, Dezoteux F, Goulenok T, Jachiet V, Jouvray M, Latu I, Ledoult E, Leurs A, Lugosi M, Martin M, Melboucy-Belkhir S, Morati-Hafsaoui C, Quemeneur T, Rohmer J, Roy-Peaud F, Sanges S, Schleinitz N, Staumont-Salle D, Taillé C, Terriou L, Tieulie N, Koenga JDE, Schwarb L, Panel K, Kahn JE, Groh M; COHESion study group. Lefèvre G, et al. Among authors: blade js. Allergy. 2025 Apr;80(4):1100-1110. doi: 10.1111/all.16463. Epub 2025 Jan 5. Allergy. 2025. PMID: 39757773
Development and Validation of the FIP Score for the Screening of FIP1L1::PDGFRA-Associated Hypereosinophilic Syndrome.
Stammler R, Vallée A, Rohmer J, Grardel N, Abisror N, Chahla WA, Ackermann F, Baudet A, Belfeki N, Ben Abdelali R, Bidet A, Bladé JS, Bleuse S, Bonnotte B, Bouderbala MA, Cayuela JM, Chebrek S, Dion J, Dossier A, Duployez N, Faguer S, Flandrin-Gresta P, Galicier L, Godon C, Grall M, Jachiet V, Jouvray M, Latu I, Ledoult E, Lengline E, Leurs A, Lhermitte L, Lifermann F, Limal N, Lioger B, Lugosi M, Machelart I, Martin M, Martis N, Mauvieux L, Melboucy-Belkhir S, Mohr C, Moulis G, Mozicconacci MJ, Naguib D, Néel A, Nicolini FE, Outh R, Panel K, Preudhomme C, Puyade M, Quemeneur T, Queyrel Moranne V, Rey J, Rousselot P, Schleinitz N, Slama B, Staumont-Salle D, Taillé C, Terriou L, Tréfond L, Viallard JF, Kahn JE, Lefèvre G, Groh M; COHESion, CEREO and GBMHM groups. Stammler R, et al. Among authors: blade js. J Allergy Clin Immunol Pract. 2025 Nov;13(11):3066-3076.e2. doi: 10.1016/j.jaip.2025.09.009. Epub 2025 Sep 22. J Allergy Clin Immunol Pract. 2025. PMID: 40992688
A phase II study of lenalidomide and rituximab (R2) combination in patients with high-risk refractory/relapsed diffuse large B-cell lymphoma.
Noel R, Zemmour C, Montes de Oca C, Belmecheri N, Aurran-Schleinitz T, Coso D, Lopez Almeida L, Mescam L, Vey N, Bladé JS, Slama B, Bouabdallah R, Schiano de Colella JM. Noel R, et al. Among authors: blade js. Hematology. 2023 Dec;28(1):2207948. doi: 10.1080/16078454.2023.2207948. Hematology. 2023. PMID: 37133334 Free article. Clinical Trial.
Isatuximab, lenalidomide, dexamethasone and bortezomib in transplant-ineligible multiple myeloma: the randomized phase 3 BENEFIT trial.
Leleu X, Hulin C, Lambert J, Bobin A, Perrot A, Karlin L, Roussel M, Montes L, Cherel B, Chalopin T, Slama B, Chretien ML, Laribi K, Dingremont C, Roul C, Mariette C, Rigaudeau S, Calmettes C, Dib M, Tiab M, Vincent L, Delaunay J, Santagostino A, Macro M, Bourgeois E, Orsini-Piocelle F, Gay J, Bareau B, Bigot N, Vergez F, Lebreton P, Tabrizi R, Waultier-Rascalou A, Frenzel L, Le Calloch R, Chalayer E, Braun T, Lachenal F, Corm S, Kennel C, Belkhir R, Bladé JS, Joly B, Richez-Olivier V, Gardeney H, Demarquette H, Robu-Cretu D, Garderet L, Newinger-Porte M, Kasmi A, Royer B, Decaux O, Arnulf B, Belhadj K, Touzeau C, Mohty M, Manier S, Moreau P, Avet-Loiseau H, Corre J, Facon T. Leleu X, et al. Among authors: blade js. Nat Med. 2024 Aug;30(8):2235-2241. doi: 10.1038/s41591-024-03050-2. Epub 2024 Jun 3. Nat Med. 2024. PMID: 38830994 Free PMC article. Clinical Trial.
Lurbinectedin for metastatic small-cell bladder carcinoma.
Boudin L, Patient M, Romeo E, Bladé JS, de Lesquen H. Boudin L, et al. Among authors: blade js. Eur J Cancer. 2021 Jul;151:1-2. doi: 10.1016/j.ejca.2021.04.002. Epub 2021 May 2. Eur J Cancer. 2021. PMID: 33951544 No abstract available.
Epidemiology, clinical picture and long-term outcomes of FIP1L1-PDGFRA-positive myeloid neoplasm with eosinophilia: Data from 151 patients.
Rohmer J, Couteau-Chardon A, Trichereau J, Panel K, Gesquiere C, Ben Abdelali R, Bidet A, Bladé JS, Cayuela JM, Cony-Makhoul P, Cottin V, Delabesse E, Ebbo M, Fain O, Flandrin P, Galicier L, Godon C, Grardel N, Guffroy A, Hamidou M, Hunault M, Lengline E, Lhomme F, Lhermitte L, Machelart I, Mauvieux L, Mohr C, Mozicconacci MJ, Naguib D, Nicolini FE, Rey J, Rousselot P, Tavitian S, Terriou L, Lefèvre G, Preudhomme C, Kahn JE, Groh M; CEREO and GBMHM collaborators. Rohmer J, et al. Among authors: blade js. Am J Hematol. 2020 Nov;95(11):1314-1323. doi: 10.1002/ajh.25945. Epub 2020 Sep 19. Am J Hematol. 2020. PMID: 32720700 Free article. Clinical Trial.
[Spheno orbitary metastasis mimicking meningioma].
Pecoul T, Boudin L, Junca-Laplace C, Romeo E, Moussavou P, Blade JS, Sellier A, Dagain A. Pecoul T, et al. Among authors: blade js. Presse Med. 2019 Nov;48(11 Pt 1):1339-1342. doi: 10.1016/j.lpm.2019.09.041. Epub 2019 Nov 11. Presse Med. 2019. PMID: 31727480 French. No abstract available.
34 results